LL-37 (10mg)

Description

• Composition and format
LL-37 (10 mg) is a synthetic antimicrobial peptide supplied as a lyophilized powder in a single vial. Each vial contains 10 mg of LL-37. The batch-specific Certificate of Analysis (COA) provides peptide sequence confirmation, molecular weight verification, and formulation details to support method-level reproducibility and documentation control in research environments.

• Analytical verification
Each lot is qualified at 99%+ purity by high-performance liquid chromatography; peptide identity and molecular integrity are confirmed by mass spectrometry. Independent third-party laboratories corroborate in-house analytical results to maintain traceable quality metrics appropriate for research use.

• Intended research use
LL-37 is evaluated exclusively in controlled in-vitro systems examining innate immune signaling, antimicrobial peptide–mediated cellular interactions, and host-defense pathway models. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals.

• Research characteristics and applications
LL-37 is characterized by a defined amino-acid sequence and reproducible physicochemical properties relevant to peptide–membrane interaction studies. In controlled in-vitro environments, researchers employ LL-37 to investigate membrane-disruption dynamics, immune signaling modulation, inflammatory pathway activation, and cellular stress-response mechanisms. Representative applications include assay development, mechanistic pathway analysis, comparative concentration-response studies, and modeling of innate immune system interactions strictly within laboratory settings.